XML 60 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2018
Business Combinations [Abstract]  
Schedule of Research and Development Assets Acquired Other than Through Business Combination
The following table and narrative summarize our asset acquisitions during 2018, 2017, and 2016.
Counterparty
Compound(s),Therapy, or Asset
Acquisition Month
 
Phase of Development(1)
 
Acquired IPR&D Expense
Sigilon Therapeutics
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018
 
Pre-clinical
 
$
66.9

AurKa Pharma, Inc.
AK-01, an Aurora kinase A inhibitor
June 2018
 
Phase I
 
81.8

ARMO
Cancer therapy - pegilodecakin
June 2018
 
Phase III
 
1,475.8

Anima Biotech
Translation inhibitors for selected neuroscience targets
July 2018
 
Pre-clinical
 
30.0

SIGA Technologies, Inc.
Priority Review Voucher
October 2018
 
Not applicable
 
80.0

Chugai Pharmaceutical Company
OWL833, an oral non-peptidic GLP-1 receptor agonist
October 2018
 
Pre-clinical
 
50.0

NextCure, Inc.
Immuno-oncology cancer therapies
November 2018
 
Pre-clinical
 
28.1

Dicerna Pharmaceuticals
Cardio-metabolic disease, neurodegeneration, and pain
December 2018
 
Pre-clinical
 
148.7

Hydra Biosciences
TRPA1 antagonists program for the potential treatment of chronic pain syndromes
December 2018
 
Pre-clinical
 
22.6

 
 
 
 
 
 
 
CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017
 
Phase III
 
857.6

KeyBioscience AG
Multiple molecules for treatment of metabolic disorders
July 2017
 
Phase II
 
55.0

Nektar Therapeutics
Immunological therapy - NKTR-358
August 2017
 
Phase I
 
150.0

CureVac AG
Cancer vaccines
November 2017
 
Pre-clinical
 
50.0

 
 
 
 
 
 
 
AstraZeneca
Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814
December 2016
 
Phase I
 
30.0

(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.